Literature DB >> 25432158

Steroid sidestep: evading androgen ablation by abiraterone.

Nima Sharifi1.   

Abstract

Tumor mechanisms of abiraterone resistance in clinical prostate cancer are not well defined. Chen and colleagues report that a T878A androgen receptor mutation occurs in a subset of patients progressing while receiving abiraterone, suggesting that this may be a therapeutically exploitable mechanism of abiraterone resistance in castration-resistant prostate cancer. ©2014 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25432158      PMCID： PMC4359949          DOI： 10.1158/1078-0432.CCR-14-2899

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  14 in total

1.  A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer.

Authors:  Kai-Hsiung Chang; Rui Li; Barbara Kuri; Yair Lotan; Claus G Roehrborn; Jiayan Liu; Robert Vessella; Peter S Nelson; Payal Kapur; Xiaofeng Guo; Hamid Mirzaei; Richard J Auchus; Nima Sharifi
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

2.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens.

Authors:  J Veldscholte; C Ris-Stalpers; G G Kuiper; G Jenster; C Berrevoets; E Claassen; H C van Rooij; J Trapman; A O Brinkmann; E Mulder
Journal:  Biochem Biophys Res Commun       Date:  1990-12-14       Impact factor: 3.575

3.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

4.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

5.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Authors:  Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Journal:  Science       Date:  2009-04-09       Impact factor: 47.728

6.  Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Authors:  Gerhardt Attard; Alison H M Reid; Timothy A Yap; Florence Raynaud; Mitch Dowsett; Sarah Settatree; Mary Barrett; Christopher Parker; Vanessa Martins; Elizabeth Folkerd; Jeremy Clark; Colin S Cooper; Stan B Kaye; David Dearnaley; Gloria Lee; Johann S de Bono
Journal:  J Clin Oncol       Date:  2008-07-21       Impact factor: 44.544

7.  Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.

Authors:  Gerhardt Attard; Alison H M Reid; Richard J Auchus; Beverly A Hughes; Amy Mulick Cassidy; Emilda Thompson; Nikhil Babu Oommen; Elizabeth Folkerd; Mitch Dowsett; Wiebke Arlt; Johann S de Bono
Journal:  J Clin Endocrinol Metab       Date:  2011-12-14       Impact factor: 5.958

Review 8.  Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences.

Authors:  K-H Chang; C E Ercole; N Sharifi
Journal:  Br J Cancer       Date:  2014-05-27       Impact factor: 7.640

9.  Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Authors:  Gerhardt Attard; Alison H M Reid; Roger A'Hern; Christopher Parker; Nikhil Babu Oommen; Elizabeth Folkerd; Christina Messiou; L Rhoda Molife; Gal Maier; Emilda Thompson; David Olmos; Rajesh Sinha; Gloria Lee; Mitch Dowsett; Stan B Kaye; David Dearnaley; Thian Kheoh; Arturo Molina; Johann S de Bono
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

Review 10.  Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer.

Authors:  Roberta Ferraldeschi; Nima Sharifi; Richard J Auchus; Gerhardt Attard
Journal:  Clin Cancer Res       Date:  2013-03-07       Impact factor: 12.531
View more
  2 in total

1.  [Antihormonal therapy in prostate cancer : Side effects].

Authors:  C H Ohlmann; P Thelen
Journal:  Urologe A       Date:  2017-04       Impact factor: 0.639

Review 2.  Allosteric alterations in the androgen receptor and activity in prostate cancer.

Authors:  Takuma Uo; Stephen R Plymate; Cynthia C Sprenger
Journal:  Endocr Relat Cancer       Date:  2017-09       Impact factor: 5.678
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.